TAGCyx Biotechnologies Inc.

11:30 AM - 11:45 AM (JST), Tuesday, March 5, 2019 ・ 2nd Floor
TAGCyx provides unique DNA aptamer with proprietary artificial nucleic acid base. Aptamer is an alternative but better option to antibody. Our innovative technology platform, named Xenoligo®, utilises 'unnatural' nucleic acid base pairs (Ds and Px) on top of natural nucleotide. Our base pair can be amplified with PCR, thus generation of aptamer using the process called SELEX is easier and faster than conventional aptamer technologies. Incorporating just Ds molecule which is hydrophobic, our DNA aptamer shows high steric diversity and binds to protein target hydrophobically. Therefore, our DNA aptamers can achieve high affinity with the Kd as high as pico molar order, and high specificity to various therapeutic targets.

We seek collaboration opportunity with pharmaceutical companies and biotech ventures to generate new Xenoligo®, for their targets of interest as API or delivery tools.
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Japan
Year Founded:
10y
Main Therapeutic Focus:
Lead Product in Development:
TAGX-0004
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
8